Combined Antithrombotic Therapy for Acute Coronary Syndrome

 

 Buy Article Permissions and Reprints

ABSTRACT

Remarkable therapeutic advances in the treatment of acute coronary syndromes (ACS) have been made with combined antithrombotic therapy. Aspirin is accepted as standard therapy in the management of ACS but has significant limitations, including intolerance, resistance, and peptic ulceration. With the intravenous platelet glycoprotein IIb/IIIa inhibitors and the new thienopyridine clopidogrel, the options for acute and chronic antiplatelet therapy have expanded. Recently, the combination of antiplatelet therapy and oral anticoagulation has gained much interest and has been shown to be effective in secondary prevention of ACS. This article summarizes important recent findings on the background of existing pathological and clinical knowledge to provide an understanding of the basis of current combined antithrombotic therapy.

REFERENCES

• 1 Hamm C W, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines.  Lancet . 2001;  358 1533-1538
  CrossrefPubMedGoogle Scholar
• 2 Gawaz M. Platelets and primary hemostasis. In: Blood Platelets Stuttgart: Thieme 2001
  Google Scholar
• 3 Schrör K. Antiplatelet drugs. A comparative review.  Drugs . 1995;  50 7-28
  PubMedGoogle Scholar
• 4 Crowther M A, Ginsberg J S, Hirsh J. Practical aspects of anticoagulant therapy. In: Robert W, Colman et al., eds. Hemostasis and Thrombosis Basic Principles and Clinical Practice, 4th ed. Philadelphia, Baltimore, New York: Lippincott Williams & Wilkins 2000
  Google Scholar
• 5 Holme P A, Orvim U, Hamers M J. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis.  Arterioscler Thromb Vasc Biol . 1997;  17 646-653
  CrossrefPubMedGoogle Scholar
• 6 Kroll M H, Hellums J D, McIntire L V, Schafer A I, Moake J L. Platelets and shear stress.  Blood . 1996;  88 1525-1541
  PubMedGoogle Scholar
• 7 Ruggeri Z M. New insights into the mechanisms of platelet adhesion and aggregation.  Semin Hematol . 1994;  31 229-239
  PubMedGoogle Scholar
• 8 Clemetson K J, Clemetson J M. Platelet collagen receptors.  Thromb Haemost . 2001;  86 189-197
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Massberg S, Gawaz M, Grüner S. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo.  J Exp Med . 2003;  197 41-49
  CrossrefPubMedGoogle Scholar
• 10 Mehta P. Aspirin in the prophylaxis of coronary artery disease.  Curr Opin Cardiol . 2002;  17 552-558
  CrossrefPubMedGoogle Scholar
• 11 Weber A A, Zimmermann K C, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance.  Lancet . 1999;  353 900
  PubMedGoogle Scholar
• 12 Helgason C M, Bolin K M, Hoff J A. Development of aspirin resistance in persons with previous ischemic stroke.  Stroke . 1994;  25 2331-2336
  CrossrefPubMedGoogle Scholar
• 13 Cambria-Kiely J A, Gandhi P J. Possible mechanisms of aspirin resistance.  J Thromb Thrombolysis . 2002;  13 49-56
  CrossrefPubMedGoogle Scholar
• 14 Howard P A. Aspirin resistance.  Ann Pharmacother . 2002;  36 1620-1624
  CrossrefPubMedGoogle Scholar
• 15 Gum P A, Kottke-Marchant K, Poggio E D. Profile and prevalence of aspirin resistance in patients with cardiovascular disease.  Am J Cardiol . 2001;  88 230-235
  CrossrefPubMedGoogle Scholar
• 16 Eikelboom J W, Hirsh J, Weitz J I, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.  Circulation . 2002;  105 1650-1655
  CrossrefPubMedGoogle Scholar
• 17 Weber A A, Przytulski B, Schanz A, Hohlfeld T, Schrör K. Towards a definition of aspirin resistance: a typological approach.  Platelets . 2002;  13 37-40
  CrossrefPubMedGoogle Scholar
• 18 CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE).  Lancet . 1996;  384 1329-1339
  PubMedGoogle Scholar
• 19 Müller I, Seyfarth M, Rüdiger S. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.  Heart . 2001;  85 92-93
  CrossrefPubMedGoogle Scholar
• 20 The ESPS-2 Group. European stroke prevention study 2: efficacy and safety data.  J Neurol Sci . 1997;  151 41-51
  CrossrefPubMedGoogle Scholar
• 21 Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  Br Med J . 2002;  324 71-86
  PubMedGoogle Scholar
• 22 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy.  Br Med J . 1994;  308 159-168
  PubMedGoogle Scholar
• 23 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.  Br Med J . 1994;  308 81-106
  PubMedGoogle Scholar
• 24 Helgason C M, Bolin K M, Hoff J A. Development of aspirin resistance in persons with previous ischemic stroke.  Stroke . 1994;  25 2331-2336
  CrossrefPubMedGoogle Scholar
• 25 Schömig A, Neumann F J, Kastrati A. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.  N Engl J Med . 1996;  334 1084-1089
  CrossrefPubMedGoogle Scholar
• 26 Leon M B, Baim D S, Popma J J. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.  N Engl J Med . 1998;  339 1665-1671
  CrossrefPubMedGoogle Scholar
• 27 Urban P, Macaya C, Rupprecht H J. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).  Circulation . 1998;  98 2126-2132
  PubMedGoogle Scholar
• 28 Bertrand M E, Legrand V, Boland J. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.  Circulation . 1998;  98 1597-1603
  PubMedGoogle Scholar
• 29 Bertrand M E, Rupprecht H J, Urban P, Gershlick A H, Investigators F T. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS).  Circulation . 2000;  102 624-629
  PubMedGoogle Scholar
• 30 Moussa I, Oetgen M, Roubin G. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.  Circulation . 1999;  99 2364-2366
  PubMedGoogle Scholar
• 31 Berger P B, Bell M R, Rihal C S. Clopidogrel versus ticlopidine after intracoronary stent placement.  J Am Coll Cardiol . 1999;  34 1891-1894
  CrossrefPubMedGoogle Scholar
• 32 Mishkel G J, Aguirre F V, Ligon R W, Rocha-Singh K J, Lucore C L. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting.  J Am Coll Cardiol . 1999;  34 1884-1890
  CrossrefPubMedGoogle Scholar
• 33 Steinhubl S R, Berger P B, Mann III T J. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (CREDO).  JAMA . 2002;  288 2411-2420
  CrossrefPubMedGoogle Scholar
• 34 Yusuf S, Zhao F, Mehta S R, Chrolavicius S, Tognoni G, Fox K K, The CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.  N Engl J Med . 2001;  345 494-502
  CrossrefPubMedGoogle Scholar
• 35 Mehta S R, Yusuf S, CURE Study Investigators. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.  Eur Heart J . 2000;  24 2033-2041
  PubMedGoogle Scholar
• 36 Mehta S R, Yusuf S, Peters R J. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.  Lancet . 2001;  358 527-533
  CrossrefPubMedGoogle Scholar
• 37 Gawaz M, Seyfarth M, Müller I. Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement.  Am J Cardiol . 2001;  87 332-336
  CrossrefPubMedGoogle Scholar
• 38 Steinhubl S R, Lauer M S, Mukherjee D P. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions.  J Am Coll Cardiol . 1998;  32 1366-1370
  CrossrefPubMedGoogle Scholar
• 39 Steinhubl S R, Ellis S G, Wolski K, Lincoff A M, Topol E J. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial.  Circulation . 2001;  103 1403-1409
  PubMedGoogle Scholar
• 40 Järemo P, Lindahl T L, Fransson S G, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel.  J Int Med . 2002;  252 233-238
  PubMedGoogle Scholar
• 41 Quinn M J, Plow E F, Topol E J. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?.  Circulation . 2002;  106 379-385
  CrossrefPubMedGoogle Scholar
• 42 The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy.  N Engl J Med . 1998;  339 436-443
  CrossrefPubMedGoogle Scholar
• 43 Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998 338: 1488-1497
  Google Scholar
• 44 Patel M R, Roe M T. Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation.  Drugs Aging . 2002;  19 633-646
  PubMedGoogle Scholar
• 45 Simoons M L, GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.  Lancet . 2001;  357 1915-1924
  CrossrefPubMedGoogle Scholar
• 46 Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997 349: 1429-1435
  Google Scholar
• 47 Cannon C P, Weintraub W S, Demopoulos L A. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.  N Engl J Med . 2001;  344 1879-1887
  CrossrefPubMedGoogle Scholar
• 48 Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during instability in coronary artery disease.  Lancet . 2000;  356 9-16
  CrossrefPubMedGoogle Scholar
• 49 Moliterno D J, Yakubov S J, DiBattiste P M. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.  Lancet . 2002;  360 355-360
  CrossrefPubMedGoogle Scholar
• 50 Topol E J, Mark D B, Lincoff A M. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting.  Lancet . 1999;  354 2019-2024
  CrossrefPubMedGoogle Scholar
• 51 The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease.  Lancet . 1990;  336 827-830
  CrossrefPubMedGoogle Scholar
• 52 Holdright D, Patel D, Cunningham D. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina.  J Am Coll Cardiol . 1994;  24 39-45
  PubMedGoogle Scholar
• 53 Wallis D E, Boden W E, Califf R. Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina.  Am Heart J . 1991;  122 949-954
  CrossrefPubMedGoogle Scholar
• 54 Oler A, Whooley M A, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.  JAMA . 1996;  276 811-815
  CrossrefPubMedGoogle Scholar
• 55 Cohen M, Demers C, Gurfinkel E P. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus intravenous unfractionated heparin, in non-Q-wave coronary events.  Am J Cardiol . 1998;  82 19L-24L
  CrossrefPubMedGoogle Scholar
• 56 Antman E M, McCabe C H, Gurfinkel E P. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.  Circulation . 1999;  100 1593-1601
  PubMedGoogle Scholar
• 57 Antman E M, Cohen M, Radley D. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.  Circulation . 1999;  100 1602-1608
  CrossrefPubMedGoogle Scholar
• 58 Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial.  Lancet . 1999;  353 429-438
  CrossrefPubMedGoogle Scholar
• 59 Brouwer M A, Verheugt F WA. Oral anticoagulation for acute coronary syndromes.  Circulation . 2002;  105 1270-1274
  CrossrefPubMedGoogle Scholar
• 60 Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction.  Lancet . 1997;  350 389-396
  CrossrefPubMedGoogle Scholar
• 61 Fiore L D, Ezekowitz M D, Brophy M T, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study.  Circulation . 2002;  105 557-563
  CrossrefPubMedGoogle Scholar
• 62 van Es F R, Jonker J J, Verheugt F W, Deckers J W, Grobbee D E. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.  Lancet . 2002;  360 109-113
  CrossrefPubMedGoogle Scholar
• 63 Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction.  N Engl J Med . 2002;  347 969-974
  CrossrefPubMedGoogle Scholar
• 64 Huynh T, Theroux P, Bogaty P, Nasmith J, Solymoss S. Aspirin, warfarin, or combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery.  Circulation . 2001;  103 3069-3074
  PubMedGoogle Scholar
• 65 The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina.  J Am Coll Cardiol . 2001;  37 475-484
  CrossrefPubMedGoogle Scholar
• 66 Anand S S, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.  JAMA . 1999;  282 2058-2067
  CrossrefPubMedGoogle Scholar
• 67 Vinik A, Flemmer M. Diabetes and macrovascular disease.  J Diabetes Compl . 2002;  16 235-245
  PubMedGoogle Scholar
• 68 Tschoepe D, Driesch E, Schwippert B, Lampeter E F. Activated platelets in subjects at increased risk of IDDM. Denis study group.  Diabetologia . 1997;  40 573-577
  CrossrefPubMedGoogle Scholar
• 69 Tschoepe D, Rauch U, Schwippert B. Platelet-leukocyte cross-talk in diabetes mellitus.  Horm Metab Res . 1997;  29 631-635
  Article in Thieme ConnectPubMedGoogle Scholar
• 70 Davi G, Gresele P, Violi F. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease.  Circulation . 1997;  96 69-75
  PubMedGoogle Scholar
• 71 Shechter M, Merz C N, Paul-Labrador M J, Kaul S. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease.  J Am Coll Cardiol . 2000;  35 300-307
  CrossrefPubMedGoogle Scholar
• 72 Bhatt D L, Marso S P, Lincoff A M, Wolski K E, Ellis S G, Topol E J. Abciximab reduces mortality in diabetics following percutaneous coronary intervention.  J Am Coll Cardiol . 2000;  35 922-928
  CrossrefPubMedGoogle Scholar
• 73 Marso S P, Lincoff A M, Ellis S G. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.  Circulation . 1999;  100 2477-2484
  PubMedGoogle Scholar
• 74 Roffi M, Chew D P, Mukherjee D. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.  Circulation . 2001;  104 2767-2771
  CrossrefPubMedGoogle Scholar
• 75 Bhatt D L, Marso S P, Hiesh A T, Ringleb P A, Hacke W, Topol E J. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.  Am J Cardiol . 2002;  90 625-628
  CrossrefPubMedGoogle Scholar